Home Newsfeeds Centessa Pharmaceuticals Q3 EPS $(0.57) Down From $(0.45) YoY

Centessa Pharmaceuticals Q3 EPS $(0.57) Down From $(0.45) YoY

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.57) per share. This is a 26.67 percent decrease over losses of $(0.45) per share from the same period last year.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.57) per share. This is a 26.67 percent decrease over losses of $(0.45) per share from the same period last year.

YouTube Stars’ Energy Drink Under FDA Review After Senate Majority Leader Raises Concern

By Vandana Singh

July 13, 9:26 AM

The FDA is currently assessing concerns raised by Senate Majority Leader Chuck Schumer about the high caffeine content in a popular energy drink called Prime Energy. The drink, founded by YouTube stars Logan Paul and KSI, is allegedly being marketed to children and teens.

CELH

EF Hutton Initiates Coverage On Merus with Buy Rating, Announces Price Target of $35

By Benzinga Newsdesk

January 5, 5:42 AM

EF Hutton analyst Tony Butler initiates coverage on Merus (NASDAQ:MRUS) with a Buy rating and announces Price Target of $35.

MRUS

Wolfe Research Reiterates Outperform on ZoomInfo Technologies, Lowers Price Target to $30

By Benzinga Newsdesk

February 7, 12:56 PM

Wolfe Research analyst Alex Zukin reiterates ZoomInfo Technologies (NASDAQ:ZI) with a Outperform and lowers the price target from $37 to $30.

Nu Skin Enterprises Sees Q2 EPS $0.45-$0.55 Vs $0.61 Est.; Q2 Revenue $485M-$525M Vs $526.75M Est.; FY23 EPS $2.41-$2.81 Vs $2.55 Est.; Revenue $2.03B-$2.18B Vs $2.09B Est.

By Happy Mohamed

May 3, 4:16 PM

Q2 and Full-year 2023 Outlook Q2 2023 Revenue: $485 to $525 million; (14) to (6)% • Approximately (1) to (2)% FX impact Q2 2023

NUE

Centessa Pharmaceuticals Q3 EPS $(0.57) Down From $(0.45) YoY

Related Posts

YouTube Stars’ Energy Drink Under FDA Review After Senate Majority Leader Raises Concern

EF Hutton Initiates Coverage On Merus with Buy Rating, Announces Price Target of $35

Wolfe Research Reiterates Outperform on ZoomInfo Technologies, Lowers Price Target to $30

Nu Skin Enterprises Sees Q2 EPS $0.45-$0.55 Vs $0.61 Est.; Q2 Revenue $485M-$525M Vs $526.75M Est.; FY23 EPS $2.41-$2.81 Vs $2.55 Est.; Revenue $2.03B-$2.18B Vs $2.09B Est.